Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 28, 2015

Primary Completion Date

March 2, 2017

Study Completion Date

March 2, 2017

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

modified FOLFIRINOX regimen

Modified FOLFIRINOX regimen consisted of oxaliplatin at a dose of 60 mg per square meter, given as a 2-hour intravenous infusion, after 60 minutes, of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion, immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector. This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus, followed by a continuous intravenous infusion of 2400 mg per square meter over a 46-hour period every 2 weeks

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02440958 - Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial | Biotech Hunter | Biotech Hunter